Spondyloarthritis and COVID-19
COVID-19 and our rheumatic diseases remains a hot topic. With the availability of vaccines and new therapeutics, many of our patients are now fully vaccinated and boosted.
Recommendations – Good & Bad (5.27.2022)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
Increasing Corticosteroid Use in Non-Hospitalized COVID-19
JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.
Long COVID Manifestations
MMWR
The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome. Long COVID appears to affect up to 20% of those who survive COVID-19 infection.
The Inflammation Reflex (5.20.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.
Methotrexate Monitoring (5.13.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
$30 Billion and Counting (4.29.2022)
Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Pre-exposure Prophylaxis for COVID-19 (4.22.22)
Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients
Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).
Evusheld as Protective Therapy in High Risk COVID-19 Patients
A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19.
Male vs. Female Responders (4.15.2022)
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Social
Autoimmune Dz may be assoc w/ new-onset Atrial Fibrillation, esp in women. Population-based UK Biobank found significant increases for AFib in Rheumatic fever w/o CVD (HR 1.47), Crohn’ (1.23), UC(1.17), RA (1.39), PAN (1.82), SLE (1.82), PSS (2.32) https://t.co/rpIiztUfg9 https://t.co/FWmLiZ6x1S
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Should Kids w/ MIS-C get the COVID vaccine? Yes - study of 385 pt > 5 yrs w/ Hx of multisystem inflammatory syndrome showed no serious adverse events after COVID-19 vaccination. The safety profile of COVID-19 vax is same as gen population https://t.co/dr2QBQsMhE? https://t.co/WbsUuYEsez
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
On Wednesday 12/21 the FDA approved tocilizumab (Actemra; 8 mg/kg, 60-min IV infusion ) for hospitalized COVID-19 on steroids, supplemental O2 & req ventilation, or ECMO; 1st MAb approved for COVID-19; Prev EUA issued in June 2021 https://t.co/BswLu4ZY5O https://t.co/7gpPkeoPZ4
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
COVID-19 Vaccine Responses in Rheumatic Disease Patients
Nature Reviews Rheumatology features a review of three notable papers that address the impact of SARS-CoV-2 vaccination on people with inflammatory rheumatic disease.
https://t.co/R9UM3amPRR. https://t.co/WmHyVKdsxw
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
During 2021–22 FLU season, 6% of hosp pedi-influenza pts had SARS-CoV-2 coinfection; these required more respiratory support. Risk of influenza death augmented by not recv vaccination (flu or covid), no antiviral Rx, comorbidities & coinfx w/COVID https://t.co/bfjeClHflW https://t.co/YTOEnNSQQN
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Recent CDC/MMWR report shows Paxlovid x 5days (including those w/ prior COVID or vaccination), had a 51% lower hospitalization rate within 30 days after diagnosis than those not prescribed Paxlovid. Use it irrespective of vaccination status https://t.co/CBc1VBSDFR https://t.co/EC8QGaFrb3
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
TIME Mag - "Why Masks Still Matter". 1) COVID is still out there; 2) Influenza on the rise. Authors write "With limited yet mixed data, we would be wise to ...err on the side of masking in high risk, indoor crowded public settings..." https://t.co/l8jiTwAdZz https://t.co/0QUKJDOhjs
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
Does Evusheld shield people living with rheumatic diseases?
Dr. Yuz Yusof ( @Yuz6Yusof) discusses three key abstracts from #ACR22 on Evusheld findings.
https://t.co/wYl6Wpd5Fs https://t.co/7T7u4czNOX
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 4 months ago
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at #ACR22
https://t.co/DEUykGt8pT https://t.co/sz8GRRGrPH
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Impact of COVID 19 on Pregnancies in Women with RMD
Dr. Cassy Sims ( @DrCassySims) discusses abstract 0950 at #ACR22.
https://t.co/qbFRV5P3eP https://t.co/cmS4n15L5e
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
